Engineering universal cells that evade immune detection

doi:10.1038/s41577-019-0200-1

Review

. 2019 Dec;19(12):723-733.

doi: 10.1038/s41577-019-0200-1. Epub 2019 Aug 15.

Engineering universal cells that evade immune detection

Robert Lanza¹, David W Russell², Andras Nagy^{3

4

5}

Affiliations

¹ Astellas Institute for Regenerative Medicine, Marlborough, MA, USA. robert.lanza@astellas.com.
² Universal Cells, Inc., Seattle, WA, USA.
³ Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Ontario, Canada.
⁴ Australian Regenerative Medicine Institute, Monash University, Melbourne, Victoria, Australia.
⁵ panCELLa, Inc., Toronto, Ontario, Canada.

PMID: 31417198
DOI: 10.1038/s41577-019-0200-1

Review

Engineering universal cells that evade immune detection

Robert Lanza et al. Nat Rev Immunol. 2019 Dec.

. 2019 Dec;19(12):723-733.

doi: 10.1038/s41577-019-0200-1. Epub 2019 Aug 15.

Authors

Robert Lanza¹, David W Russell², Andras Nagy^{3

4

5}

Affiliations

¹ Astellas Institute for Regenerative Medicine, Marlborough, MA, USA. robert.lanza@astellas.com.
² Universal Cells, Inc., Seattle, WA, USA.
³ Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Ontario, Canada.
⁴ Australian Regenerative Medicine Institute, Monash University, Melbourne, Victoria, Australia.
⁵ panCELLa, Inc., Toronto, Ontario, Canada.

PMID: 31417198
DOI: 10.1038/s41577-019-0200-1

Abstract

The prospect of transplanting cells and tissues without the risk of immune rejection or the need for powerful immunosuppressive drugs is the 'holy grail' of transplantation medicine. Now, with the advent of pluripotent stem cells, CRISPR-Cas9 and other gene-editing technologies, the race to create 'off-the-shelf' donor cells that are invisible to the immune system ('universal cells') has started. One important approach for creating such cells involves the manipulation of genes required for immune recognition, in particular HLA class I and II proteins. Other approaches leverage knowledge of immune-cloaking strategies used by certain bacteria, viruses, parasites, the fetus and cancer cells to induce tolerance to allogeneic cell-based therapies by modifying cells to express immune-suppressive molecules such as PD-L1 and CTLA4-Ig. Various academic groups as well as biotechnology and pharmaceutical companies are on the verge of bringing these therapies into the clinic.

PubMed Disclaimer

Cited by

Downregulating human leucocyte antigens on mesenchymal stromal cells by epigenetically repressing a β₂-microglobulin super-enhancer.
Wang F, Li R, Xu JY, Bai X, Wang Y, Chen XR, Pan C, Chen S, Zhou K, Heng BC, Wu X, Guo W, Song Z, Jin SC, Zhou J, Zou XH, Ouyang HW, Liu H. Wang F, et al. Nat Biomed Eng. 2024 Oct 21. doi: 10.1038/s41551-024-01264-w. Online ahead of print. Nat Biomed Eng. 2024. PMID: 39433971
Considerations for the development of iPSC-derived cell therapies: a review of key challenges by the JSRM-ISCT iPSC Committee.
Madrid M, Lakshmipathy U, Zhang X, Bharti K, Wall DM, Sato Y, Muschler G, Ting A, Smith N, Deguchi S, Kawamata S, Moore JC, Makovoz B, Sullivan S, Falco V, Al-Riyami AZ. Madrid M, et al. Cytotherapy. 2024 Nov;26(11):1382-1399. doi: 10.1016/j.jcyt.2024.05.022. Epub 2024 Jun 12. Cytotherapy. 2024. PMID: 38958627 Review.
Hypoimmunogenic human iPSCs expressing HLA-G, PD-L1, and PD-L2 evade innate and adaptive immunity.
Tsuneyoshi N, Hosoya T, Takeno Y, Saitoh K, Murai H, Amimoto N, Tatsumi R, Watanabe S, Hasegawa Y, Kikkawa E, Goto K, Nishigaki F, Tamura K, Kimura H. Tsuneyoshi N, et al. Stem Cell Res Ther. 2024 Jul 2;15(1):193. doi: 10.1186/s13287-024-03810-4. Stem Cell Res Ther. 2024. PMID: 38956724 Free PMC article.
Non-invasive quantification of stem cell-derived islet graft size and composition.
Lithovius V, Lahdenpohja S, Ibrahim H, Saarimäki-Vire J, Uusitalo L, Montaser H, Mikkola K, Yim CB, Keller T, Rajander J, Balboa D, Barsby T, Solin O, Nuutila P, Grönroos TJ, Otonkoski T. Lithovius V, et al. Diabetologia. 2024 Sep;67(9):1912-1929. doi: 10.1007/s00125-024-06194-5. Epub 2024 Jun 14. Diabetologia. 2024. PMID: 38871836 Free PMC article.
Manufacturing and validation of small-diameter vascular grafts: A mini review.
Hernandez-Sanchez D, Comtois-Bona M, Muñoz M, Ruel M, Suuronen EJ, Alarcon EI. Hernandez-Sanchez D, et al. iScience. 2024 Apr 29;27(6):109845. doi: 10.1016/j.isci.2024.109845. eCollection 2024 Jun 21. iScience. 2024. PMID: 38799581 Free PMC article. Review.

See all "Cited by" articles

References

1. Brent, L. A History of Transplantation Immunology. (Academic Press, San Diego, 1996).
1. Min, D. I. & Monaco, A. P. Complications associated with immunosuppressive therapy and their management. Pharmacotherapy 11, 119S–125S (1991). - PubMed
1. Bix, M. et al. Rejection of class I MHC-deficient haemopoietic cells by irradiated MHC-matched mice. Nature 349, 329–331 (1991). - PubMed
1. Liao, N. S., Bix, M., Zijlstra, M., Jaenisch, R. & Raulet, D. MHC class I deficiency: susceptibility to natural killer (NK) cells and impaired NK activity. Science 253, 199–202 (1991). - PubMed
1. Taylor, C. J. et al. Banking on human embryonic stem cells: estimating the number of donor cell lines needed for HLA matching. Lancet 366, 2019–2025 (2005). - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Other Literature Sources
- The Lens - Patent Citations
Research Materials
- NCI CPTC Antibody Characterization Program

[1] Brent, L. A History of Transplantation Immunology. (Academic Press, San Diego, 1996).

[2] Brent, L. A History of Transplantation Immunology. (Academic Press, San Diego, 1996).

[3] Min, D. I. & Monaco, A. P. Complications associated with immunosuppressive therapy and their management. Pharmacotherapy 11, 119S–125S (1991). - PubMed

[4] Min, D. I. & Monaco, A. P. Complications associated with immunosuppressive therapy and their management. Pharmacotherapy 11, 119S–125S (1991). - PubMed

[5] Bix, M. et al. Rejection of class I MHC-deficient haemopoietic cells by irradiated MHC-matched mice. Nature 349, 329–331 (1991). - PubMed

[6] Bix, M. et al. Rejection of class I MHC-deficient haemopoietic cells by irradiated MHC-matched mice. Nature 349, 329–331 (1991). - PubMed

[7] Liao, N. S., Bix, M., Zijlstra, M., Jaenisch, R. & Raulet, D. MHC class I deficiency: susceptibility to natural killer (NK) cells and impaired NK activity. Science 253, 199–202 (1991). - PubMed

[8] Liao, N. S., Bix, M., Zijlstra, M., Jaenisch, R. & Raulet, D. MHC class I deficiency: susceptibility to natural killer (NK) cells and impaired NK activity. Science 253, 199–202 (1991). - PubMed

[9] Taylor, C. J. et al. Banking on human embryonic stem cells: estimating the number of donor cell lines needed for HLA matching. Lancet 366, 2019–2025 (2005). - PubMed

[10] Taylor, C. J. et al. Banking on human embryonic stem cells: estimating the number of donor cell lines needed for HLA matching. Lancet 366, 2019–2025 (2005). - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Engineering universal cells that evade immune detection

Affiliations

Engineering universal cells that evade immune detection

Authors

Affiliations

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Research Materials

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources

Research Materials